79-year-old male patient with a 2-point improvement in IGA PN-S
Current PN therapy: DUPIXENT 300 mg Q2W
This adult patient was an actual patient (not a clinical trial participant) treated with DUPIXENT for ≥24 weeks. Scoring was designated by the healthcare professional. Because this patient was a real-world patient, other factors may have influenced treatment results, and individual results may vary.
RESULTS
![](/dam/jcr:f83501fc-6688-40c8-9054-101e5294d7f2/iga-pn-hand-before.jpg)
![](/dam/jcr:a3526609-d433-433e-a9e5-b6fa4a8f7e09/iga-pn-hand-before-mob.jpg)
![](/dam/jcr:0fdae134-71bc-47ea-a0fb-27a2764c37da/iga-pn-hand-after.jpg)
![](/dam/jcr:209a8c39-01ac-4431-922c-c8f6989dbf73/iga-pn-hand-after-mob.jpg)
RESULTS
![](/dam/jcr:b1fd21a4-f94e-4025-86d0-208993209c1c/iga-pn-hand2-before.jpg)
![](/dam/jcr:2659f082-34a1-425b-8c5a-ef736aaa8141/iga-pn-hand2-before-mob.jpg)
![](/dam/jcr:78b50f94-cded-48a6-88cf-a7e8b3bbbfce/iga-pn-hand2-after.jpg)
![](/dam/jcr:f17e7f85-9712-4d10-be96-6fbcbdf676b9/iga-pn-hand2-after-mob.jpg)
SIGNIFICANT NODULE CLEARANCE
DUPIXENT patients achieved significant reduction in nodules vs placebo at Week
24 (secondary endpoint)1-3
- A nominal difference was observed at Week 4 (9% with DUPIXENT vs 1% with placebo) and at Week 12 (32% with DUPIXENT vs 12% with placebo)3
Definitive conclusions cannot be made for results earlier than 24 weeks in PRIME. Data were not multiplicity controlled.
PRIME2
- At Week 4, 8% of patients treated with DUPIXENT vs 6% with placebo had nodule clearance. A significantly greater proportion of DUPIXENT patients achieved nodule clearance at Week 12 (26% with DUPIXENT vs 12% with placebo; P=0.019) and Week 24 (45% with DUPIXENT vs 16% with placebo; P<0.001)1-3
Definitive conclusions cannot be made for results at timepoints other than Week 12 and 24 in PRIME2. Data were not multiplicity controlled.
DUPIXENT DEMONSTRATED SIGNIFICANT NODULE CLEARANCE
PRIME
At baseline:
29% of patients
had
an IGA PN-S
score
of 4 (over
100 nodules)2,b
71% of patients
had an IGA PN-S
score
of 3
(20-100
nodules)2
At Week 24:
48% of DUPIXENT
patients
improved to an
IGA PN-S score of
0 or 1 (5 nodules
or fewer)
compared with
18% with
placebo1,2
Illustrative representation of nodule clearance based on clinical trial results.
Actual individual results may vary.
to see results
![](/dam/jcr:24d2ccf8-7d38-44e3-ab8a-7ff135e8ce6f/baseline_slider-bg.png)
![](/dam/jcr:24d2ccf8-7d38-44e3-ab8a-7ff135e8ce6f/baseline_slider-bg.png)
![](/dam/jcr:f4c5a348-8115-470d-8d43-85cea2b30e10/week_24-slider-bg.png)
![](/dam/jcr:f4c5a348-8115-470d-8d43-85cea2b30e10/week_24-slider-bg.png)
Illustrative representation of nodule clearance based on clinical trial results. Actual individual results may vary.
IGA PN-S ranges from 0 (clear, no nodules) to 1 (almost clear, ≤5 nodules), 2 (mild, 6-19 nodules), 3 (moderate, 20-99 nodules), and 4 (severe, ≥100 nodules).
- In PRIME2, 38% of patients had 100 or more nodules at baseline, with 45% of all DUPIXENT patients achieving 5 nodules or fewer at Week 24 vs 16% with placebo1,2
bAll study participants had ≥20 nodules upon screening and at Day 1 (inclusion criteria).
DUPIXENT showed consistent efficacy regardless of patients’ atopic
background1,4
IGA PN-S, Investigator’s Global Assessment PN-Stage; Q2W, once every 2 weeks; SD, standard deviation.
Dosage and administration
Thinking about
prescribing DUPIXENT?
Find the
information you
need to get started.